FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497306088> ?p ?o ?g. }

• W1497306088 endingPage "74" @default.
• W1497306088 startingPage "2969" @default.
• W1497306088 abstract "Although previous clinical study revealed that bortezomib combined with dexamethasone had improved the outcomes of relapsed or refractory multiple myeloma (RRMM), the optimal dose combinations of bortezomib and dexamethasone remain unknown. This trial aimed to observe the efficacy and safety of different dose combinations of bortezomib and dexamethasone in the treatment of RRMM patients in China.A total of 168 patients with relapsed multiple myeloma (MM) who were refractory to at lest two prior treatments were enrolled in this multicenter, open-label, non-randomized, prospective clinical trial. Twenty patients received 1.3 mg/m(2) of bortezomib twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles and oral or intravenous dexamethasone 20 mg on the day of and after each bortezomib dose (group 1); 66 patients received less than 1.3 mg/m(2) (0.7 - 1.0 mg/m(2)) of bortezomib and dexamethasone 20 mg on the same schedule (group 2); 37 patients received 1.3 mg/m(2)2 of bortezomib and dexamethasone 40 mg (group 3) and 45 patients received less than 1.3 mg/m(2) (0.7 - 1.0 mg/m(2)) of bortezomib and dexamethasone 40 mg (group 4). The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0.The median age of groups 1 to 4 was 61, 62, 56, and 60 years, respectively. Most patients were in stages II/III of MM and the most common subtype was IgG. The rate of overall response to bortezomib and dexamethasone of group 1 to 4 was 72.2% (13/18), 73.8% (48/65), 78.8% (26/33) and 78.0% (32/41) (P = 0.91), including a complete response rate of 22.2% (4/18), 20.0% (13/65), 33.3% (11/33) and 29.3% (12/41) (P = 0.67), respectively. There was no statistical significance in time to progression and overall survival among these 4 groups (P > 0.05). The most commonly adverse events of any grade in the entire 4 groups were fatigue, gastrointestinal effects, peripheral neuropathy and thrombocytopenia, and there was no significance in the number of adverse events among the 4 groups (P > 0.05) except that peripheral neuropathy was reported more frequently in group 3 (36.3%) than in group 2 (13.8%, P < 0.05) and group 4 (14.6%, P < 0.05).The combination of bortezomib and dexamethasone was associated with high responses in Chinese RRMM patients. No significant differences of efficacy were detected in different dose combinations of bortezomib and dexamethasone. Moreover, low dose of bortezomib reduced the incidence of peripheral neuropathy without affecting outcome in the treatment of patients with RRMM in China." @default.
• W1497306088 created "2016-06-24" @default.
• W1497306088 creator A5000279889 @default.
• W1497306088 creator A5037029781 @default.
• W1497306088 creator A5042479541 @default.
• W1497306088 creator A5054109124 @default.
• W1497306088 creator A5055577592 @default.
• W1497306088 creator A5064348871 @default.
• W1497306088 creator A5075861470 @default.
• W1497306088 creator A5083332923 @default.
• W1497306088 creator A5090495842 @default.
• W1497306088 date "2011-10-01" @default.
• W1497306088 modified "2023-09-27" @default.
• W1497306088 title "Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China." @default.
• W1497306088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22040537" @default.
• W1497306088 hasPublicationYear "2011" @default.
• W1497306088 type Work @default.
• W1497306088 sameAs 1497306088 @default.
• W1497306088 citedByCount "7" @default.
• W1497306088 countsByYear W14973060882013 @default.
• W1497306088 countsByYear W14973060882014 @default.
• W1497306088 crossrefType "journal-article" @default.
• W1497306088 hasAuthorship W1497306088A5000279889 @default.
• W1497306088 hasAuthorship W1497306088A5037029781 @default.
• W1497306088 hasAuthorship W1497306088A5042479541 @default.
• W1497306088 hasAuthorship W1497306088A5054109124 @default.
• W1497306088 hasAuthorship W1497306088A5055577592 @default.
• W1497306088 hasAuthorship W1497306088A5064348871 @default.
• W1497306088 hasAuthorship W1497306088A5075861470 @default.
• W1497306088 hasAuthorship W1497306088A5083332923 @default.
• W1497306088 hasAuthorship W1497306088A5090495842 @default.
• W1497306088 hasConcept C121332964 @default.
• W1497306088 hasConcept C126322002 @default.
• W1497306088 hasConcept C141071460 @default.
• W1497306088 hasConcept C142424586 @default.
• W1497306088 hasConcept C143998085 @default.
• W1497306088 hasConcept C197934379 @default.
• W1497306088 hasConcept C2776364478 @default.
• W1497306088 hasConcept C2777478702 @default.
• W1497306088 hasConcept C2780401358 @default.
• W1497306088 hasConcept C71924100 @default.
• W1497306088 hasConcept C87355193 @default.
• W1497306088 hasConcept C90924648 @default.
• W1497306088 hasConceptScore W1497306088C121332964 @default.
• W1497306088 hasConceptScore W1497306088C126322002 @default.
• W1497306088 hasConceptScore W1497306088C141071460 @default.
• W1497306088 hasConceptScore W1497306088C142424586 @default.
• W1497306088 hasConceptScore W1497306088C143998085 @default.
• W1497306088 hasConceptScore W1497306088C197934379 @default.
• W1497306088 hasConceptScore W1497306088C2776364478 @default.
• W1497306088 hasConceptScore W1497306088C2777478702 @default.
• W1497306088 hasConceptScore W1497306088C2780401358 @default.
• W1497306088 hasConceptScore W1497306088C71924100 @default.
• W1497306088 hasConceptScore W1497306088C87355193 @default.
• W1497306088 hasConceptScore W1497306088C90924648 @default.
• W1497306088 hasIssue "19" @default.
• W1497306088 hasLocation W14973060881 @default.
• W1497306088 hasOpenAccess W1497306088 @default.
• W1497306088 hasPrimaryLocation W14973060881 @default.
• W1497306088 hasRelatedWork W2000246028 @default.
• W1497306088 hasRelatedWork W230412469 @default.
• W1497306088 hasRelatedWork W2350480662 @default.
• W1497306088 hasRelatedWork W2362636202 @default.
• W1497306088 hasRelatedWork W2364188423 @default.
• W1497306088 hasRelatedWork W2531713994 @default.
• W1497306088 hasRelatedWork W2934354596 @default.
• W1497306088 hasRelatedWork W3030219566 @default.
• W1497306088 hasRelatedWork W3030437974 @default.
• W1497306088 hasRelatedWork W3032664604 @default.
• W1497306088 hasVolume "124" @default.
• W1497306088 isParatext "false" @default.
• W1497306088 isRetracted "false" @default.
• W1497306088 magId "1497306088" @default.
• W1497306088 workType "article" @default.